PLENARY SESSION
Genetic Predisposition to Cancer (Louise C. Strong)

SYMPOSIA
Genes, Cell Proliferation, and Antineoplastic Drugs (George F. Vande Woude)
Diagnostic, Prognostic, and Therapeutic Aspects of Tumor Suppressor Genes (David Sidrinsky)
Cell Cycle Regulation (Peggy J. Farnham)
Breast Cancer Genes (Barbara L. Weber)
Metastasis, Adhesion, and Angiogenesis: Mechanisms and Therapeutic Strategies (Marilyn M. Cornwell and Elise C. Kohn)
Novel Clinical Trials Based on Genetics and Molecular Therapeutics (Stephen H. Friend)
Apoptosis and Cancer Chemotherapy (Michael B. Kastan)
Identification and Management of Genetic-High-Risk Individuals (Albert de la Chapelle)
Demystifying the Role of Cytokines in Tumor Immunobiology: Status and Future Utility (Michael A. Caligiuri)
Telomerase and Clinical Applications (Titia de Lange)
Acute Myelocytic Leukemia (Clara Derber Bloomfield)
Prostate Cancer (Donald S. Coffey)
Colon Cancer (Margaret A. Tempero)
Signaling Pathways for Novel Therapeutics (Anthony J. Pawson)
Animal Models for Functional Analysis of Tumor Suppressor Genes (Terry A. Van Dyke)
New Techniques for Molecular Diagnostics (Eric S. Lander)
Mechanisms of Cellular Senescence (J. Carl Barrett)
Damage Response Pathways (Philip C. Hanawalt)
Gene Interactions with the Environment/Carcinogenesis (Allan Balmain)
Epidemiology and Pathogenesis of Secondary Cancers (Frederick P. Li)

How Robust Are Antisense/Third Strand Techniques for Gene Disruption?

“MEET-THE-EXPERT” SUNRISE SESSIONS
Angiogenesis
Gene Therapy (Jack A. Roth)
Strategies for Drug Development (Daniel D. Von Hoff)
Advances in Our Molecular Understanding of Lymphoproliferative Disease (A. Thomas Look)
FHIT Gene (Kay Huebner)
Cancer Vaccines (David P. Carbone)
Lung Cancer
Costimulatory Molecules in Tumor Immunity
New Approaches to Overcoming Multidrug Resistance (Alan F. List)
Advances in Oncologic Imaging (Michael J. Welch)
Retinoids and Cancer Prevention (Waun Ki Hong)
Mechanisms of Regulation of p53 Function (Guillermina Lozano)
Cell Cycle Control of Genetic Stability (Geoffrey Wahl)
Farnesyl Transferase Inhibitors (Allen I. Oliff)
Bioinformatics/Genomics
DNA Methylation in Cancer (Stephen B. Baylin)
Chemoprevention in Transgenic Animals (James M. Phang)
Advances in Stem Cell Transplantation
Psychosocial Issues in Cancer
Advances in the Management of AIDS-related Malignancies (Ellen G. Feigal)
Recent Developments in Our Understanding of Minimal Residual Disease (John G. Gribben)
Ovarian Cancer Update (Robert C. Bast, Jr.)
The Biological Basis of the New International Classification of Lymphoma (Elaine S. Jaffe)
Recent Developments in Radiotherapy
Colon Cancer Genes
Extracellular Connections
Barrett’s Esophageal Cancer and Tumor Progression Models (Brian J. Reid)
H. Pylori
Transcriptional Models and Drug Discovery (William G. Kaelin)

METHODS WORKSHOPS AND EDUCATIONAL SESSIONS
To be announced

Abstract Deadline: November 12, 1996

Further Information: AACR Office · Public Ledger Building · Suite 816 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483 · TELEPHONE: (215) 440-9300 · FAX: (215) 440-9313 · Email: aacr@aacr.org · For up-to-date information visit the AACR Website at http://www.aacr.org
Cancer Epidemiology
Biomarkers

& Prevention

An Official Journal of the American Association for Cancer Research • Copublished by the American Society of Preventive Oncology

American Association for Cancer Research, Inc.
Executive Director and Director of Publications
Margaret Fox

Publications Staff
Associate Director of Publications
Mary Anne Menneke
Manager, Editorial Services
Heide M. Punzay
Senior Staff Editor
Lisa A. Chippendale
Staff Editors
Michael J. Beveridge
Kathleen C. Assenmacher
Pamela R. Arnold
Laurie B. Baker
Staff Assistant
Mary Ellen Perring
Administrative Coordinator
Holly M. Haskins
Senior Editorial Assistant
Theresa A. Griffith
Editorial Assistants
Valerie L. Samuel
Andrea Conrad
Bethann Massarella
Administrative Staff
Adam D. Blisten
Controller
Joan D. Ritchie
Coordinator, Financial Operations
George L. Moore
Manager, Meetings and Exhibits
Jeffrey M. Ruben
Meeting Planner
Carole L. Kanoff
Public Information Coordinator
Jenny Anne Horst-Martz
Assistant to the Executive Director
Ruth E. Fortson
Membership Development Coordinator
Robin E. Felder
Administrative Assistant
Margaret A. Pickels
Systems Specialist
Lydia I. Rodriguez
Secretary
Malika I. Wright
Editorial Assistant
Diana F. Certo
Office Clerk
James J. Waters
Data Entry Clerk
Robert A. Simms II
Office of the Editor-in-Chief
Editorial Assistant
Cheryl C. Carter

Editor-in-Chief
Pelayo Correa

Associate Editors
W. Robert Bruce
Webster K. Cavenee
Joseph F. Fraumeni, Jr.
Ellen R. Gritz
Curtis C. Harris
Stephen S. Hecht
Barbara S. Hulka
Fred F. Kadlubar
Laurence N. Kolonel
Frederick P. Li
W. Thomas London
Thomas E. Moon
Abraham M. Y. Nomura
John D. Potter
James A. Swenberg
Steven R. Tannenbaum
Alice S. Whitemore
Chung S. Yang
Mimi C. Yu

Assistant Editor
Elizabeth T. H. Fontham

Editorial Advisory Board
Hans-Olov Adami
Bruce K. Armstrong
Helmut Bartsch
Valerie Beral
Leslie Bernstein
John S. Bertram
Joan R. Bloom
William J. Blot
John D. Boice, Jr.
George E. Bonney
Roberd M. Bostick
Ricardo R. Brentani
Eva Buiai
Neil E. Caporaso

Wong-Ho Chow
Philip Cole
K. Michael Cummings
Susan J. Curry
Janet Daling
Mary Daly
Eduardo DeStefani
Paul F. Engstrom
Virginia L. Erster
Michael Fiore
David Forman
Eduardo L. Franco
Yu-Tang Gao
E. Robert Greenberg
Raymond S. Greenberg
Peter Greenwald
F. Peter Guengerich
Rodrigo Guerreiro
Clark W. Heath, Jr.
Kathy J. Helzlsouer
Elizabeth A. Holly
Wuau Ki Hong
Geoffrey R. Howe
Mary Claire King
Leo J. Kinlen
Paul Kleihues
Alfred G. Knudson, Jr.
Bernard Levin
Lance A. Liotta
Martin Lipkin
Richard R. Love
Thomas Mack
Frank L. Meyskens, Jr.
Christopher J. Michejda
Rodney F. Minchin
John D. Minna
Ruggero Montesano
John J. Mulvihill
Alvaro Muñoz
Nubia Muñoz

Alfred I. Neugut
Gilbert S. Omenn
C. Tracy Orleans
David L. Page
Frederica Perera
Nicholas L. Petrakis
John P. Pierce
Miriam C. Poirier
Bruce A. J. Ponder
Ross Prentice
Barbara Rymer
Nathaniel Rothman
George C. Roush
Jose Russo
Jonathan M. Samet
Arthur Schatzkin
Mark H. Schiffman
David Schottenfeld
Paul A. Schulte
Peter Shields
Roy E. Shore
Margaret R. Spitz
Louise C. Strong
Takahsi Sugimura
G. Marie Swanson
Eiichi Tahara
Bruce Trock
Sally Vernon
Michael J. Wargovich
Lee W. Wattenberg
I. Bernard Weinstein
John H. Weisburger
Noel S. Weiss
Ainsley Weston
Walter C. Willett
Rodger J. Winn
Gerald N. Wogan
Sandar R. Wolman
Ernst L. Wynder
Regina Ziegler

Cancer Epidemiology, Biomarkers & Prevention is published monthly, one volume annually, by the American Association for Cancer Research, Inc. Except for members of the American Association for Cancer Research, all subscriptions are payable in advance to Cancer Epidemiology, Biomarkers & Prevention, P. O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997 or (201) 627-2427; FAX: (201) 627-5872], to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsutsunii Bldg., 13-12, Shimibashi l-chome, Minato-ku, Tokyo 105, Japan; Tel. (03) 502-6471. Nonmembers of the American Association for Cancer Research within the United States may subscribe to Volume 5 (1996) of Cancer Epidemiology, Biomarkers & Prevention at the rate of $85 (individual nonmembers) or $215 (institutional nonmembers, including postage. Institutional and individual nonmembers outside of the United States should add $40 to their respective rates to offset periodicals postage costs. Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: Member Services, American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: Cancer Epidemiology, Biomarkers & Prevention, P. O. Box 3000, Denville, NJ 07834. Copies of the journal which are undeliverable because of address changes will be destroyed. Accelerated mailing of all AACR journals to AACR members in Japan is fully supported by a generous grant from the Banyu Pharmaceutical Company, Tsukuba, Japan.
Notice to Members of the American Association for Cancer Research
Officers for 1996–1997
President: Louise C. Strong, UT M. D. Anderson Cancer Center, Houston, TX 77030
President-Elect: Donald S. Coffey, Johns Hopkins University School of Medicine, Baltimore MD 21287-2101
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 816, Philadelphia, PA 19106-3483

Annual Dues
The annual dues of active members of the American Association for Cancer Research are $160, $50 of which may be applied toward a subscription to Cancer Epidemiology, Biomarkers & Prevention. Corresponding members of the Association will be charged an appropriate fee to offset periodicals postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, American Association for Cancer Research, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Telephone: (215)440-9300; FAX: (215)440-9313.

Submission of Manuscripts
Cancer Epidemiology, Biomarkers & Prevention publishes original research on cancer causation and prevention in humans, linking three previously unintegrated disciplines: epidemiology, biomarkers, and prevention. Topics include descriptive, analytical, biochemical, and molecular epidemiology; the use of biomarkers to study the neoplastic and premalignant processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention. Manuscripts that address individual subjects in any of the three disciplines are welcome as well as manuscripts with an interdisciplinary approach. All submissions undergo peer review. Papers should be sent directly to Pelayo Correa, M. D., Editor-in-Chief, CEBP, Dept. of Pathology, Louisiana State University Medical Center, 1901 Perdido Street, New Orleans, LA 70112-1393. See Instructions for Authors (page i of this issue) for further information concerning submissions.

Back Issues and Single Copy Sales of the Journal
Copies of back stock of the journal may be ordered from Cancer Epidemiology, Biomarkers & Prevention, P. O. Box 3000, Denville, NJ 07834; Telephone: (800) 875-2997 or (201) 627-2427; FAX: (201) 627-5872. As long as supplies permit, single copies will be sold by this company at $12.50/copy. Orders outside the U.S. add $3.00/copy to offset postage costs.

Advertisements
Advertisement insertion orders and copy must be received one month prior to the date of issue in which the advertisement is to be published. The journal is mailed by approximately the 10th day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 155 South White Horse Pike, Berlin, NJ 08009; Telephone: (609) 768-9360; FAX: (609) 753-0064.

Copyright and Permissions
Authors who wish to publish in Cancer Epidemiology, Biomarkers & Prevention must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including without limitation rights of reproduction, derivation, distribution, sale, and display of the work, in whole or in part, in any and all forms of media now or hereafter known. Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material. The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AACR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors before corresponding with the AACR.

Those who wish to photocopy articles should contact the AACR Publications Department [Telephone: (215) 440-9300; FAX: (215) 440-9355].

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., by the American Society of Preventive Oncology, or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Cancer Epidemiology, Biomarkers & Prevention is indexed in Chemical Abstracts, Current Contents/CMP, Index Medicus, MEDLINE, and the BIOSIS Previews® Database. This journal is printed on acid-free paper.

Cancer Epidemiology, Biomarkers & Prevention (ISSN 1055-9965) is published monthly by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for $50 annually for members, $85 for individual nonmembers, and $215 for institutional nonmembers. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to Cancer Epidemiology, Biomarkers & Prevention, P. O. Box 3000, Denville, NJ 07834. Copyright 1996 by the American Association for Cancer Research, Inc. Printed in the U.S.A.
CANCER EPIDEMIOLOGIST

A tenure track position is available immediately in the National Cancer Institute (NCI), National Institutes of Health (NIH), for a scientific investigator with expertise and experience in molecular and cancer epidemiology. Candidates should have a doctorate in epidemiology or an M.D./D.V.M. with at least a master’s degree in epidemiology. She/he should have demonstrated experience and advanced understanding of epidemiological methods. Experience in the design, conduct, and analysis of large, multicenter epidemiological studies domestically and abroad is also required. Candidates should have a strong understanding of molecular biological processes and should have demonstrable experience in epidemiological studies with large biospecimen collections. Prior knowledge and experience in the study of female gynecologic tumors and tumors with a viral etiology are desirable. The successful candidate will develop an independent research program focused on the investigation of co-factors (both host and environmental) involved in the etiology of virus-related gynecologic and other tumors. Interested individuals should send a cover letter, curriculum vitae, brief summary of research interests and experience, copies of selected publications, and three letters of reference to:

Ms. Judy Schwadron, Program Analyst
Division of Cancer Epidemiology and Genetics
National Cancer Institute
Executive Plaza North Room 543
Bethesda, MD 20892

The closing date for applications is January 15, 1997. The National Institutes of Health is an Equal Opportunity Employer.

Hit our Home Page on the World Wide Web!

http://www.aacr.org

Our web site features:

AACR scientific meeting schedule

Table of Contents of AACR journals

Instructions for Authors

Information about AACR Research Fellowships and Travel Awards

Plus . . . The latest AACR newsletter, and much more!
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Basic and Clinical Aspects of Breast Cancer

March 7-12, 1997
The Keystone Resort, Keystone, Colorado

CONFERENCE CHAIRPERSONS
J. Carl Barrett / Research Triangle Park, NC
Karen S.H. Antman / New York, NY
Mary-Claire King / Seattle, WA

SCIENTIFIC PROGRAM

Keynote Addresses
Mary-Claire King / Seattle, WA
Karen S.H. Antman / New York, NY

Basic Biology of the Breast
José Russo / Philadelphia, PA
Marc E. Lippman / Washington, D.C.
C. Kent Osborne / San Antonio, TX

Molecular and Cellular Aspects of Breast Cancer
Jerry W. Shay / Dallas, TX
Mina J. Bissell / Berkeley, CA
Martha R. Stampfer / Berkeley, CA

Genetic Predisposition to Breast Cancer
David E. Goldgar / Lyon, France
P. Andrew Futreal / Durham, NC

Mechanisms of Hormone Action
V. Craig Jordan / Chicago, IL
Myles A. Brown / Boston, MA
Kenneth S. Korach / Research Triangle Park, NC

BRCA1 and BRCA2 Function/Biochemistry
Roy A. Jensen / Nashville, TN
Wen-Hwa Lee / San Antonio, TX
David M. Livingston / Boston, MA
Frank J. Calzone / Thousand Oaks, CA

Experimental Models of Breast Cancer
Tak W. Mak / Toronto, Ontario, Canada
Roger W. Wiseman / Research Triangle Park, NC
Michael N. Gould / Madison, WI

Epidemiology of Breast Cancer
Walter C. Willett / Boston, MA
Maureen Henderson / Seattle, WA
Malcolm C. Pike / Los Angeles, CA
Mary S. Wolff / New York, NY

Clinical Aspects of Breast Cancer
Judy E. Garber / Boston, MA
Jeffrey T. Holt / Nashville, TN
M. John Kennedy / Baltimore, MD

Applicants are encouraged to submit abstracts for poster presentation.
Application deadline: January 3, 1997

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
aacr@aacr.org (E-mail)
http://www.aacr.org
Acknowledgment to Reviewers

The Editor-in-Chief and Associate Editors gratefully acknowledge their colleagues who reviewed manuscripts for Cancer Epidemiology, Biomarkers & Prevention, from September 1995 through September 1996.

A
Michael Alavanja  
David Alberts  
Christine Ambrosone

B
Joan Bailey-Wilson  
Thomas Baranowski  
Robert Barbieri  
John A. Baron  
Roshan Bastani  
Terri H. Beaty  
Douglas A. Bell  
Adrienne Benedich  
William Bennett  
Al Bowen Benson  
Sandra Bigner  
Ranjan P. Bird  
Gladys Block  
Melissa Bondy  
Alton L. Boynton  
H. Leon Bradlow  
Patricia Braley  
David Brenner  
Louise Brinon  
Anton Brooks  
Robert D. Burk

C
Kenneth Cantor  
Andre Castonguay  
Anne Cats  
Laishun Chen  
Vivien Chen  
Margie Lee Clapper  
Larry Clark  
Steven K. Clinton  
Gerhard A. Coetsee  
Nancy H. Colburn  
Graham Colditz  
Kathleen Conway  
Linda Cook  
Daniel Cramer  
Rosemary Cress  
Pamela Crowell

D
Anthony B. DeAngelo  
Edward DeAntoni  
Joakin Dillner  
Zora Djuric

E
David Earnest  
David Eastmond  
Brenda Edwards  
Charis Eng  
Shelley Enger

F
M. Brian Fennerty  
Capri-Mara Fillmore  
Gary Friedman  
Lenore Kohlmeir  
Paul J. Kostynick  
Norman I. Krinsky  
Alan Kristal  
Lewis Kuller  
Larry Kushi

G
Richard Gallager  
Marilie Gammon  
Susan M. Gapstur  
Seymour Garewal  
Eugene Gerner  
E. Giovannucci  
Wayne Glasgow  
David Goldgar  
Alisa Goldstein  
Bernard Goldstein  
Gary Goodman  
Marc Greenblatt  
Seymour Grufferman

H
Robert Haile  
Susan Hankinson  
Tamara Harris  
Patricia Hartge  
Steven Hartley  
Aage Haugen  
Richard Hayes  
John A. Heidell  
Brian Henderson  
Charles Hennekens  
Steve Heresting  
Alan Hildesheim  
Walter N. Hittelman  
Monica Hollstein  
Peter R. Holt  
Jun-Yan Hong  
Waan Ki Hong  
Pamela Horn-Ross  
Peter M. Howley  
Ann Hsiung  
I. C. Hsu  
Jay Hunt  
Mary Hunt  
David Hunter

I
Peter D. Inskip  
Richard Irons  
Christina Iasono

J
Paul Jacobsen  
Judith Jacobson  
Raymond Jones

K
Maragaret R. Karagas  
William Kaufmann  
Larry K. Keefer  
Ann Kennedy  
Mimi Kim  
Karin Klein  
A. J. P. Klein-Szanto  
Gary Kociba

L
David La  
Carlo La Vecchia  
Johanna Lampe  
Loic Le Marchand  
Juan Lechago  
J. J. Lee  
Marion Lee  
Paul Levine  
Albert Lin  
Loren Lipworth  
Marcy List  
Stephanie Joan London  
Matthew Longnecker  
George W. Lucier  
Roger Luckmann  
Joanne R. Lupton

M
Nathan Mantel  
Lawrence Marnett  
James Marshall  
Thomas J. Mason  
Greg Matalabowski  
Carl McDougal  
Katherine McGlynn  
Joseph McLaughlin  
Patricia McNicol  
Curtis J. Mettin  
Tony Miller  
Robert Millikan  
Sidney Mirvish  
Patricia G. Moorman  
Dexter Morris  
Suzanne Morris  
Mark A. Morse  
Nancy Mueller  
Hasan Mukhtar  
Sharon Murphy  
Joshua Muscat

N
Philip Nasca  
Dan Nebert  
Polly Newcomb  
Harold Newmark

O
Thomas O'Brien  
Andrew Olshan

P
Domenico Palli  
Julie Parsonnet  
Electra D. Paskett  
Trevor M. Penning  
Catherine Perez  
Linda Picken  
Malcombe Pike  
Harlan Pinto  
Nancy Potishman  
Michael Press

Q
Jenny Quintana

R
Steven M. Rappaport  
David Reardon  
Tim Rebeck  
Bandaru S. Reddy  
Boris Renjifo  
Kenneth Renton  
Peggy Reynolds  
Elio Riboli  
John Richie  
Lynn Ries  
Michael Rip  
Harvey A. Risch  
Cheryl Ritenbaugh  
Dean Roberts  
Leslie Robinson  
Zee A. Ronai  
Birgit Rose  
David P. Rose  
Miriam P. Rossin  
Bernardo Ruiz  
David Russell

S
Audrey Saffat  
Robert S. Sandler  
Regina Santella  
J. Edward Schneider  
Stephen Schwartz  
Thomas A. Sellers  
Richard E. Severson  
Yih-Hong Shiao  
David Sidransky  
Vishwa Singh  
Rashmi Sinha  
Martha Slattery  
Theresa Smith  
Meir Stampfer  
Frank Stanczyk  
Janet Stanford  
Grant Stemmermann  
Richard Stevens  
Gary Stoner  
Daniel Straum  
Howard Strickler  
Sara Strom  
Christine Swanson  
Christine Szarka

T
Philip R. Taylor
1018 Acknowledgment to Reviews

David Thomas  Acknowledgment to Reviews
Harold Thompson
Michael Thun
Mark Thierz
Raymond Tice
Paolo Toniolo
Bill Travis
Lois Travis
Glen Trivers

David Thomas
Harold Thompson
Michael Thun
Mark Thierz
Raymond Tice
Paolo Toniolo
Bill Travis
Lois Travis
Glen Trivers

U
Giske Ursin
V
Thomas L. Vaughan
John Vena
Victor Vogel
Linda Voght

W
Scholom Wachholder
Bob Wallace
Li-Dong Wang
Qingyi Wei
Larry Whiteley
James Willey
Mary Wolff
Anna Wu

Y
James Yager
Guang-yu Yang
Wei-Cheng You

Z
Jane Zapka
Zuo-Feng Zhang
Lue Ping Zhao
Author Index / Volume 5

A
Abbondandolo, A., 559
Adami, H.-O., 509
Ahn, D. K., 85
Ahnen, D. J., 437
Ahsan, H., 513, 457
Aicin, M., 343, 907
Akerkar, S. A., 521, 645
Albanes, D., 487
Alberts, D. S., 343, 349, 907
Amadon, C., 749
Andersen, A., 3
Anderson, G., 815
Andersen, K. E., 63
Andersson, C., 393
Andersson, S.-O., 509
Andrade, O., 41
Anttila, A., 801
Anttila, S., 33
April, A., 559
Arber, N., 457
Arella, M., 271
Arseneau, J., 271
Ashley, R., 541
Asirwathan, J. E., 285
Assereto, P., 559
Aste, H., 559
Auckley, D. H., 631

B
Bajdik, C. D., 419
Balbi, J., 515
Ballard-Babash, R., 385
Bane, B. L., 971
Baranski, B., 297
Barnes, S., 785
Baron, J. A., 399, 425, 509, 897
Barrad, L., 179
Barrett, M. J., 487
Bartsch, H., 693, 795
Baskett, C., 849
Basani, R., 845
Beaton, M., 217
Becker, T. M., 323
Beckmann, A.-M., 541, 879
Beckworth, D., 749
Belinsky, S. A., 631
Bell, D. A., 979
Benhamou, S., 683
Bennett, W. P., 93, 997
Bergner, J. C., 71
Bergström, R., 425, 509
Berman, E. L., 639
Bernstein, L., 753, 961
Berrucci, J., 693
Berrino, F., 917
Berwick, M., 263, 587, 879
Bhagavan, H. N., 913
Bhatnagar, V. K., 979
Bi, W., 979
Bigbee, W. L., 801
Bird, C. L., 607, 753
Bjersing, L., 393
Black, J. D., 285
Blaser, M. J., 627
Bloomfield, C. D., 867
Blot, W. J., 47, 627

Bogdan, G., 399
Bogliolo, M., 559
Boice, J. D., Jr., 93
Boilell, G., 917
Bolognesi, C., 361
Bongers, V., 955, 941
Bonner, R. B., 971
Bonney, G., 967
Boone, C. W., 657
Boorstein, R., 263
Borukhova, A., 521, 645
Bosch, F. X., 567, 853
Bostick, R. M., 109, 349, 779
Bostwick, D. G., 823
Boté, E., 385
Bouchard, C., 683
Boyd, N. F., 217
Bozzo, P., 343
Braakhuis, B. J. M., 595, 941
Bracci, P. M., 85
Bradford, C., 845
Branch, M., 907
Britton, J. A., 467
Bronstein, J. C., 53
Brooks, L. R., 979
Brown, C. C., 487
Bruce, W. R., 1013
Bueno-de-Mesquita, H. B., 673
Buia, E., 41
Bull, A. W., 53
Burk, R. D., 843
Burroughs, B., 11
Burt, R. D., 587, 879
Burt, R. W., 375
Bye, A. S., 3

C
Caan, B., 385
Caderni, G., 167
Cahill, J., 375
Campbell, D., 711
Campbell, M. K., 115, 889
Campbell, W. S., 533
Campomonesi, P., 559
Cancer and Steroid Hormone Study Group, 411
Caporaso, N. E., 693, 757, 799, 997
CARET Conoinvestigators, 815
Carlson, E., 425
Carmella, S. G., 521, 645
Carrillo, E., 41
Carroll, P. R., 993
Carp, P., 223
Carter, J. I., 541
Carzoglio, J. C., 679
Case, L. D., 721
Castelli, G., 227
Castro, D., 41
Cattolica, E., V., 993
Chan, L. C., 277
Chan, W. C., 277
Chandlerimani, M., 263
Chandler, D. W., 835
Chang, Y.-S., 47, 627
Chapman, J., 929
Chapot, B., 179

Chen, C., 727, 985
Chen, C.-D., 355
Chen, C.-J., 103, 173, 483, 613
Chen, M.-J., 147
Cheng, L., 199
Choi, W. S., 317
Chow, W.-H., 17, 47, 79
Christiansen, D. C., 687
Chutimataewin, S., 179
Chyov, P.-H., 621
Clapp, R. W., 399
Clarke, E. A., 93
Clifford, D. C., 385
Clinton, S. K., 823
Cloos, J., 941
Coccio, P., 223
Cohen, B., 297
Colby, T. V., 997
Coldman, A., 419
Collan, Y., 33
Colosimo, S. G., 135
Connig, P., 223
Conio, M., 559
Connor, T. H., 527
Conti, E., 155
Cooney, R. V., 449
Cooper, G. S., 867
Cooper, M. R., 375
Cordella, J., 337
Correa, P., 1, 477, 515, 627
Cousins, M., 217
Coward, L., 785
Crane, M. M., 639
Cranston, B., 699, 873
Crooks, L. A., 631
Crowell, J. A., 657
Crowell, R. E., 631
Custer, L. J., 449

de Wolf, C., 853
Dhingra, K., 705
Diamandis, E., 967
Dolara, P., 167
Donaldson, J. L., 835
Dorgan, J. F., 533, 923, 947
Dubin, N., 263
DuPont, W. D., 29

E
Edmond, L. M., 811
Ebya, H., 967
Einspahr, J., 343, 349
Eischen, B. T., 979
Eisenberg, E., 769
Ekholm, A., 425
Elmer, P., 779
Elwood, P. C., 673
Emenhiser, C., 823
Enger, S. M., 147, 961
Engstrom, P. F., 141, 967
Erdman, J. W., Jr., 823
Estapé, J., 337
Everson, R. B., 503

F
Falk, R. T., 533
Farzadegan, H., 173
Fay, J. R., 657
Feagins, H., 913
Fears, T. R., 835
Fedele, L., 667
Fehily, A. M., 673
Fein, J. S., 761
Feng, P., 979
Ferencyz, A., 853
Fernandez, E., 23, 433
Fernandez-Criouhet, J., 441
Fierro, L., 515
Fincham, S., 419
Fingold, J., 457
Firda, J., 337
Fleming, M., 473
Flore, C., 223
Fok, C. L., 227
Fontham, E. T. H., 515, 579
Forde, K. A., 313
Fosdick, L., 109, 349, 779
Fox, S. D., 47
Franceschi, S., 155, 433, 567
Franco, E., 271, 853
Franke, A. A., 407, 449
Frankl, H. D., 147, 607
Franz, C., 533
Fraumeni, J. F., Jr., 17, 47, 79, 627
Freedman, A. N., 285
Freedman, L. S., 375, 947
Friedman, G. D., 993
Fronza, G. N., 579
Frost, F., 861
Fuchs, D., 699
Fueger, J. J., 639
Fuentes, M., 337
Fujii, K., 461
Treat, M. R., 313
Trentham-Dietz, A., 955
Trevisan, M., 917
Trizna, Z., 191
Trump, D. L., 371
Trushin, N., 645

U
Urbina, C. E., 861
Urbini, S., 559
Ursin, G., 143
Utermahlen, W. E., 47

V
Vagstad, N., 3
Vainio, H., 33
van den Brandt, P. A., 733
van Leeuwen, F. E., 93
van Poppel, G., 733
van 't Veer, P., 441
Vaughan, T. L., 587, 879
Vaught, J. B., 835
Velasco, M., 355
Velez, R., 721
Verani, P., 227
Verhagen, H., 733
Verhoeven, D. T. H., 733
Villa, L., 271
Vineis, P., 693
Virtamo, J., 487
Visani, G., 227

Vitale, A., 227
Vivas, J., 41

W
Wacholder, S., 17
Wachter, H., 699
Wain, J. C., 687
Walboomers, J. M. M., 567
Waldmann, T. A., 873
Wang, J-S., 57, 253
Wang, L. D., 405
Wang, M., 705
Wang, Q., 467
Wargovich, M. J., 349, 355
Waye, J. D., 313
Weaver, V. M., 135
Weed, D. L., 303
Wei, Q., 199
Weinstein, I. B., 457
Weiss, J. E., 849
Weiss, L. K., 81
Weiss, N. S., 985
Weissfeld, J., 385
Welch, K., 343
Welsh, J. A., 93
West, D. W., 901
Whelan, R., 937
White, E., 495
White, J. D., 873
Wiencke, J. K., 687, 785
Wild, C. P., 179
Wilkins, L. R., 161, 449
Willett, W. C., 109
Williams, A. E., 473
Williams, A. W., 823
Williams, E., 699
Wipf, G. C., 541
Wolfe, L., 173
Wolff, M. S., 467
Wolk, A., 509
Wong, K. T., 277
Wood, J., 779
Woods, C., 349
World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives, 933
Wu, A. H., 901
Wu, M-H., 173
Wu, T-C., 483
Wu, X., 577
Wu, X. F., 527
Wurzelmann, J. I., 503

X
Xing, Y., 405
Xu, G-W., 47, 627
Xu, X., 199, 687

Y
Yancey, A. K., 753
Yang, C-S., 405
Yang, C-S., 47
Yang, P-M., 173
Yap, E., 457
Yasui, W., 461
Yeowell-O’Connell, K., 205
Yin, S., 979
Yokoyama, A., 99
Yokozaki, H., 461
Yongvanit, P., 795
You, S-L., 173, 483
You, W-C., 47, 627
You, X., 979
Young, J. F., 757
Yu, G-P., 761
Yu, H., 967
Yu, M-W., 613
Yuen, J., 399
Z
Zarba, A., 253
Zenser, T. V., 979
Zhang, B. C., 405
Zhang, B-C., 253
Zhang, J-J., 461
Zhang, T., 483
Zhang, Z-F., 285, 761
Zhao, L., 47, 627
Zhao, Y., 527
Zhou, Q., 405
Zhu, Y-R., 253
Ziegler, R. G., 835, 901
Zocchetti, C., 693
Zong, Y. S., 277
Subject Index / Volume 5

A

Abstracts
American Society of Preventive Oncology annual meeting, 233

N-Acetyltransferase
supplementation, and mutagen sensitivity, 941

N-Acetylcysteine
Aldehyde
Albumin
Alaska
African
Aflatoxinalbumin
Adults:
Adrenal
Adenomatous
Adenocarcinoma,
Actinic
A
p53
genotypes
and cancer
multiple
occupational
small
hormone
serum
dietary
risk
risk
factors,
multiple,
smoking
factors,
mutations,
exposure,
carcinoma,
exposure,
941
99
variation
annual
1
Natives
15
Americans
1
1

N-Acetyltransferase 2
within-subject caffeine metabolism
variation analysis, letter, 231, 757
Actinic keratosis
surrogate end point biomarkers
PCNA, 343
Adenocarcinoma, esophagus
risk factors, 761
Adenocarcinoma, gallbladder
p53 mutations, 461
Adenocarcinoma, gastric cardia
risk factors, 761
Adenocarcinoma, small intestine
incidence, adults, 81
Adenoma, colorectal
dietary antioxidant vitamins and, 147
serum lipids and, 607
Adenomatous polyps
hormone replacement therapy and, 779
recurrent
and body mass index, 313
Adrenal cancer
mortality
smoking and, U.S. veterans, 79
Adults: see also Men; Women
small intestine adenocarcinomas and carcinoid tumors, incidence, 81
Aerodigestive tract
upper, cancer
human papillomavirus and, review, 567
multiple, cancer incidence among relatives and, 595
Aflatoxin-albumin adducts
animal vs human carcinogenesis, 179
occupational styrene and styrene oxide exposure, 205
temporal patterns, Qidong County, 253
Aflatoxin B1 adducts
multiple risk factors, hepatocellular carcinoma, 613
African Americans
biomarkers of omega-3 fatty acid consumption, prostatic carcinoma, 115
Alaska Natives
cancer incidence rates, 749
Albumin adducts: see also Aflatoxin-albumin adducts
occupational styrene and styrene oxide exposure, 205
Alcohol
and adenocarcinomas of esophagus and gastric cardia, 761
and oral epithelial dysplasia, 769
Aldehyde dehydrogenase-2
genotypes
esophageal cancer and, Japanese males, 99
Aleuts
cancer incidence rates, 749
American Indians
breast cancer survival, New Mexico, 861
ovarian cancer incidence and mortality, New Mexico, 323
American Society of Preventive Oncology
20th annual meeting
abstracts, 233
meeting report, 579
4-Aminobiphenyl-hemoglobin adducts
CYP1A2 activity and, 693
Anal cancer
risk
GSTM1 genotypes and, population-based case-control study, 985
Androgen
serum levels
and breast cancer risk, 533
and prostate cancer, 621
Androstenedione
serum levels
reliability and validity, 923
Antibodies
H. pylori
and precancerous gastric lesions, high-risk Chinese, 627
Antigen
hepatitis B surface
aflatoxin-albumin adducts and, Qidong County, 253
human leukocyte
distribution, adult T-cell leukemia/lymphoma, 873
MN
cervical Pap smears, cervical dysplasia, 549
proliferating cell nuclear
computer-assisted image analysis, large intestine, 109
surrogate end point biomarker, actinic keratosis, 343
prostate-specific
nipple aspirate fluid levels, and breast cancer risk, 967
tumor-associated
DD23, bladder cancer marker, 971
Antioxidants
dietary intake, and colorectal adenomas, 147
tissue
and postmenopausal breast cancer, EURAMIC study, 441
Apocrine change
papillary
breast cancer risk, 29
Apoptosis
cervical cancer, 329
Arizona
American Indian women
breast cancer survival, 861
Arsenic
exposure
drinking water, toenail concentrations, 849
mitomycin C hypersensitivity and, 103
Asbestos
occupational exposure, bladder cancer, 33
Asian-Americans
breast cancer risk
tofu and, 901
B
Barrett's esophagus
cyclin D1 expression, 457
intestinal-type
p53 mutations, 559
Basal cell carcinoma, skin
risk factors
cancer, chemical exposure and medical history, 419
Bel-2 protein
cervicovaginal, invasive cervical cancer, 329
Benzidine
exposure
GSTM1 and bladder cancer, workers, 979
Biomarkers
arsenic exposure
mitomycin C hypersensitivity, 103
bladder cancer
DD23, characterization, 971
cadmium exposure
metallothionein gene expression, 297
valafenamic
MN antigen, cervical Pap smear, 549
colon cancer
aberrant crypts, 355
immune activation
serum, patterns, 699
measurements from nonlinear calibration
curves, variabilit, 57
modification by phenethyl isothiocyanate, lung tumors, 645
omega-3 fatty acid consumption, prostatic carcinoma, 115
surrogate end point, editorial, 947
PCNA, actinic keratosis, 343
urinary, and oral leukoplakia, 521
Biopsy
colon
13-HODE dehydrogenase levels, 53
esophageal
sampling procedure, reproducibility, 405
rectal
whole crypt mitotic count, reliability, 437
Blacks
biomarkers of omega-3 fatty acid consumption, prostatic carcinoma, 115
HLA distribution, adult T-cell leukemia/lymphoma, 873
Bladder cancer
GSTM1 and, benzidine-exposed workers, 979
hematuria before, 993
markers
DD23, characterization, 971
p53 mutations, tobacco smoking, and occupational asbestos exposure, 33
risk factors, 161
Bleomycin
chromosomal lesions
and lung cancer, 527
Blood
- chlorinated hydrocarbon levels, breast cancer, 467
- organochlorine levels, postpartum, 753

Blood, peripheral
- tyrosinase mRNA, melanoma, 293
- white blood cells
- DNA adducts, floriculturists, 361

Blood, whole
- stability at 4°C, 811

Body mass index
- recurrent adenomatous polyps and, 313

Bowel: see Intestine

Brain tumors
- childhood
- maternal diet/vitamin use and, 599
- prenatal tobacco smoke exposure and, study results, 127
- tobacco smoke exposure and, 85

Brassica vegetables
- and cancer risk, review, 733

Breast
- architectural pattern, parity and, letter, 143
- malondialdehyde-DNA adducts, 705
- papillary apocrine change, breast cancer risk, 29
- soy protein and, women, 785

Breast cancer
- architectural pattern, parity and, letter, 143
- blood chlorinated hydrocarbon levels, 467
- cigarette smoking and, 399
- high-risk women
  - mailed intervention and, 71
  - postmenopausal
    - tissue antioxidants and, EURAMIC study, 441
    - risk
      - nipple aspirate PSA levels and, 967
      - serum hormone levels and, 533
      - tolu and, Asian-Americans, 901
  - risk factors
    - papillary apocrine change, 29
    - physical activity, 155
  - risk perceptions
    - and mammography stages of change, 1005
  - risk reduction
    - soya diet and, premenopausal women, 63
    - screening
      - physician examinations, mailed intervention and, 71
      - self-reported tests, validation, 721
      - survival
        - New Mexico women, 861

Breast carcinoma in situ
- incidence and treatment, regional differences, 317
- risk factors, 961

Bromodeoxyuridine
- colonic proliferation measurement, reproducibility, 349

Bronchial epithelium
- nonmalignant
  - trisomy 7, lung cancer, 631
  - metallothionein gene expression and, 297

Carcinillophy Study
- fruit and vegetable consumption and cancer mortality, 673

Caffeine
- metabolism, within-subject variation
  - analysis, letters, 231, 757

Calcium
- dietary
  - and colorectal cancer, Stockholm, 897

Calibration
- nonlinear curves
  - biomarker measurement variability, 57

Cancer: see also Carcinoma
- epidemiology
  - causal inference practice, review, 303
  - studies, brassica vegetables, risk, review, 733
- incidence
  - among relatives, and multiple upper aerodigestive tract cancers, 595
- rates, Alaska Natives, 749
- mortality
  - fruit and vegetable consumption and,
    - Caerphilly Study, 673
- rare, Werner syndrome, 239
- risk
  - brassica vegetables and, review, 733

Cancer, adrenal
- mortality
  - smoking and, U.S. veterans, 79

Cancer, anal
- risk
  - GSTM1 genotypes and, population-based case-control study, 985

Cancer, bladder
- GSTM1 and, benzidine-exposed workers, 979
- hematuria before, 993
- markers
  - DD23, characterization, 971
- p53 mutations, tobacco smoking, and occupational asbestos exposure, 33
- risk factors, 161

Cancer, breast
- architectural pattern, parity and, 143
- blood chlorinated hydrocarbon levels, 467
- cigarette smoking and, 399
- high-risk women
  - mailed intervention and, 71
  - postmenopausal
    - tissue antioxidants and, EURAMIC study, 441
    - risk
      - nipple aspirate PSA levels and, 967
      - perceptions, and mammography stages of change, 1005
- serum hormone levels and, 533
- tolu and, Asian-Americans, 901
- risk factors
  - papillary apocrine change, 29
  - physical activity, 155
  - risk perceptions
    - and mammography stages of change, 1005

Cancer, cervix
- invasive
  - HPV DNA and, 271
  - HPV-16/18 E6, p53, and bcl-2 protein, 329
- prevention, new developments, meeting report, 853
- screening
  - new developments, meeting report, 853
  - self-reported tests, validation, 721

Cancer, colon
- biomarkers
  - aberrant crypts, 355
- risk factors
  - food groups and water intake, 495

Cancer, colorectal
- diet diversity and, Northern Italy, 433
- and folate status, male smokers, 487
- NSAID use and, women, 955
- risk
  - dietary calcium, vitamin D and, 897
  - iron intake and, 503
- risk factors
  - p53 overexpression, 285

Cancer, endometrial
- familial risk, younger women, 411

Cancer, esophageal
- aldehyde dehydrogenase-2 genotypes and, Japanese males, 99
- p53 mutations, China, 277

Cancer, gastric
- H. pylori and, meeting report, 477

Cancer, head and neck
- multiple
  - cancer incidence among relatives and, 595

Cancer, invasive cerebral
- HPV DNA and, 271
- HPV-16/18 E6, p53, and bcl-2 protein, 329

Cancer, larynx
- risk
  - CYP2D6 activity and tobacco and, 683

Cancer, lower urinary tract
- risk factors, 161

Cancer, lung
- CARET prevention study
  - serum carotene, retinol, and tocopherol, 815
  - chromosomal lesions and, 527
- GSTM1 and codon 72 p53 polymorphisms, 337
- nonmalignant bronchial epithelium
  - trisomy 7, 631
- p53 mutations and occupational exposures, 997
- radiation-associated
  - p53 mutations, 93
- risk
  - dietary nitrosodimethylamine and, Uruguay, 679
  - mate drinking and, Uruguay, 515
- susceptibility
Carcinoma, nasopharyngeal
HLA type and, 879
low-risk population, 587
Cancer, ovarian
incidence and mortality, New Mexico, 323
risk
pelvic inflammatory disease and, 667
tubal ligation or hysterectomy and, 933
Cancer, pancreatic
 attributable risks, Northern Italy, 23
Cancer, prostate
circulating vitamin D metabolites and, 121
essential fatty acids and, editorial, 859
omega-3 fatty acid consumption
biomarkers, 115
risk
lifestyle factors and, Sweden, 509
omega-6 fatty acids and, 889
serum androgens and, 621
survival
ethnic variation, New Mexico, 247
Cancer, renal cell
risk factors
obesity, 17
Cancer, skin
risk factors
chemical exposures and medical history, 419
Cancer, testicular
parental use of fertilizers and, 3
Cancer, thyroid
risk factors
reproductive history and cigarette smoking, women, 419
Cancer, upper aerodigestive tract
human papillomavirus and, review, 567
multiple cancer incidence among relatives and, 595
Cancer prevention and control investigators
training programs, 141
Carbohydrates
low-fat high-carbohydrate diet, long-term effects, 217
urinary, and diet, 167
Carcinoid tumors, small intestine
incidence, adults, 81
Carcinoma: see also Cancer
afitoxin-albumin adducts, animal vs human carcinogenesis, 179
Carcinoma, basal cell
skin
chemical exposures, medical history and, 419
Carcinoma, hepatocellular
acute intermittent porphyria and, morphology and mutations, 393
afitoxin B₁-DNA adducts
multiple risk factors, 613
hepatitis C and B infections, Taiwan, 173
Carcinoma, squamous cell
skin
chemical exposures, medical history and, 419
Carcinoma in situ, breast
incidence and treatment, regional differences, 317
risk factors, 961
CARET: see Carotene and Retinol Efficacy Trial
β-Carotene
cervical intraepithelial neoplasia treatment, phase II study, 929
serum, CARET trial, 815
Carcotene and Retinol Efficacy Trial (CARET)
serum carotene, retinol, and tocopherol, 815
Carotenoids
data base
and diet assessment, 907
dietary intake
and colorectal adenomas, 147
prostate concentrations, 823
uptake and distribution, colonic epithelial cells, 913
whole blood stability at 4°C, 811
Caucasians
nasopharyngeal carcinoma
HLA type and, U.S., 879
non-Hispanic breast cancer survival, New Mexico, 861
ovarian cancer incidence and mortality, New Mexico, 323
prostatic carcinoma biomarkers of omega-3 fatty acid consumption, 115
Causal inference
practice, cancer epidemiology, review, 303
Cellular proliferation
colonic bromodeoxyuridine measurement, reproducibility, 349
diacylglycerol levels and, 937
rectal whole crypt mitotic count, reliability, 437
Cervical cancer
invasive
HPV DNA and, 271
HPV-16/18 E6, p53, and bcl-2 protein, 329
screening and prevention, new developments, meeting report, 853
self-reported screening tests, validation, 721
Cervical dysplasia biomarkers
MN antigen, cervical PAP smear, 549
Cervical intraepithelial neoplasia β-carotene treatment, phase II study, 929
Chemical exposure
squamous and basal cell carcinoma risk, skin, 419
Chemoprevention
difluoromethylornithine doses, 371
ermal growth factor receptor inhibitors, review, 657
phenylthiisothiocyanate, lung tumors, 645
Chemotherapy
cisplatin tumor response, G0 lymphocyte micronuclei and, 653
Childhood brain tumors
maternal diet/vitamin use and, 599
prenatal tobacco smoke exposure and, study results, 127
tobacco smoke exposure and, 85
Children
inner-city
environmental tobacco smoke exposure, 135
China
Daxin, Qidong County
aflatoxin-albumin adducts, temporal patterns, 253
esophageal carcinoma, p53 mutational spectrum, 277
precancerous gastric lesions
H. pylori antibodies and, high-risk population, 627
China, Northern
esophageal biopsy sampling procedure, reproducibility, 405
Chlorinated hydrocarbons
blood levels, breast cancer, 467
Chromosomal lesions
and lung cancer, 527
Chromosomes
G-banded analysis
pesticide applicators, non-Hodgkin’s lymphoma, 11
Cigarette smoking: see Smoking
Cisplatin
tumor response
G0 lymphocyte micronuclei and, osteosarcoma, 653
Colon
aberrant crypts, cancer biomarker, 355
biopsy
13-HODE dehydrogenase levels, 53
cellular proliferation
bromodeoxyuridine measurement, reproducibility, 349
diacylglycerol levels, proliferation and, 937
epithelial cells
micronutrient uptake and distribution, 913
left adenomas, serum lipids and, 607
Colon cancer
biomarkers
aberrant crypts, 355
risk
food groups and water intake, 495
Colon tumors
13-HODE dehydrogenase levels, 53
insulin promotion, rats, 1013
Colorectal adenoma
dietary antioxidant vitamins and, 147
serum lipids and, 607
Colorectal cancer
diet diversity and, Northern Italy, 433
and folate status, male smokers, 487
NSAID use and, women, 955
p53 overexpression, risk factors, 285
risk
dietary calcium, vitamin D and, 897
iron intake and, 503
Commercial soybean diets
isoflavones
quantification method, letter, 407
Computer-assisted image analysis
proliferating cell nuclear antigen, large intestine, 109
Contraceptives
oral
HPV-related cervical tumors and, 541
Cyclin D1 gene expression, Barrett’s esophagus, 457

Cytochrome P450
1A1
- Msp1 polymorphism, and lung cancer susceptibility, 687
- activity, and 4-aminobiphenyl-hemoglobin adduct levels, 693
- caffeine phenotyping, letter, 231, 757
- within-subject caffeine metabolism variation analysis, letter, 231, 757

2A6
- and liver fluke infection, 795
- activity, and larynx cancer risk, 683

D

Daidzein
- soya diet and urine, quantification method, 407

Daxin, Qidong County, People’s Republic of China
- aflatoxin-albumin adducts, temporal patterns, 253

DD23
- bladder cancer marker characterization, 971

Dehydroepiandrosterone sulfate
- serum levels
- reliability and validity, 923

Dehydrogenase
- 13-HODE, neoplastic colon tissue, 53

Diacylglycerol
- colonic levels
- proliferation and, 937

1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene
- blood levels, breast cancer, 467

Diet
- assessment
- new carotenoid data base and, 907
- diversity
- and colorectal cancer, Northern Italy, 433
- low-fat high-carbohydrate
- long-term effects, 217
- maternal
- and pediatric brain tumors, 599
- soya
- isoflavones, quantification method, letter, 407
- and steroid hormones, premenopausal women, 63
- urinary carboxydrates and, 167

Dietary antioxidant vitamins
- and colorectal adenomas, 147

Dietary calcium
- and colorectal cancer, Stockholm, 897

Dietary intervention
- low-fat high-carbohydrate, long-term effects, 217
- Polyp Prevention Trial I, 375
- Polyp Prevention Trial II, 385
- studies
- sucrose intake predictors, 167

Dietary nitrates
- and lower urinary tract cancer risk, 161

Dietary nitrosodimethylamine
- and lung cancer risk, Uruguay, 679

Dietary supplementation
- α-tocopherol and glutathione and DNA repair, 263

Difluoromethylornithine
- chemoprevention doses, 371
- toxicity evaluation, 371

Dihydrotestosterone
- serum levels
- reliability and validity, 923

7,4′-Dihydroxyflavone
- soya diet and urine, quantification method, 407

Diversity, diet
- and colorectal cancer, Northern Italy, 433

DNA
- HPV
- invasive cervical carcinoma, 271
- PCR-based assay, interlaboratory agreement, 483

DNA adducts
- aflatoxin-albumin
- animal vs human carcinogenesis, 179
- temporal patterns, Qidong county, 253
- aflatoxin B1
- multiple risk factors, hepatocellular carcinoma, 613
- albumin, occupational styrene and styrene oxide exposure, 205
- 4-aminobiphenyl-hemoglobin
- CYP1A2 activity and, 693
- hemoglobin, occupational styrene and styrene oxide exposure, 205
- malondialdehyde, breast tissue, 705
- peripheral white blood cell, floriculturists, 361
- urothelial cell, benzidine-exposed workers, 979

DNA repair
- capacity
- and lymphoblastoid cell mutagen sensitivity, 199
- dietary α-tocopherol supplementation and, 263

Drinking
- mate
- and lung cancer risk, Uruguay, 515
- and oral epithelial dysplasia, 769

Drinking water
- toenail arsenic concentrations and, 849

Drugs: see also specific drugs
- nonsteroidal anti-inflammatory and colorectal cancer, women, 955

Dysplasia, cervical
- MN antigen, cervical dysplasia, 549

Dysplasia, oral epithelial
- smoking and drinking and, 769

E

Editorial
- monthly journal, 1

Endometrial cancer
- familial risk, younger women, 411

Environmental exposures
- and karyotype, acute myelocytic leukemia, 639
- tobacco smoke, inner-city children, 135

Enzyme-linked immunosassay kit
- urinary estrogen metabolites measurement, 727

Epidermal growth factor
- receptor inhibitors, potential chemopreventives, review, 657

Epithelial cells
- colonic
- micronutrient uptake and distribution, 913
- proliferative kinetics, diacylglycerol levels and, 937

Epithelial dysplasia, oral
- smoking and drinking and, 769

Epithelium
- nonmalignant bronchial trisomy 7, lung cancer, 631

Eskimos
- cancer incidence rates, 749

Esophageal adenocarcinoma
- risk factors, 761

Esophageal biopsy
- sampling procedure, reproducibility, 405

Esophageal cancer
- aldehyde dehydrogenase-2 genotypes and, Japanese males, 99
- p53 mutations, China, 277

Esophagus, Barrett’s
- cyclin D1 expression, 457
- intestinal-type p53 mutations, 559

Estradiol
- serum levels
- reliability and validity, 923
- reproducibility, 835

Estrogen
- serum levels
- and breast cancer risk, 533
- urinary metabolites
- enzyme-linked immunosassay kit measurement, 727

Estriol
- serum levels
- reliability and validity, 923
- reproducibility, 835

Estrone sulfate
- serum levels
- reliability and validity, 923
- reproducibility, 835

Ethnic variations
- prostate cancer survival, New Mexico, 247

EUROMEC: see European Community Multicentre Study on Antioxidants, Myocardial Infarction, and Cancer of the Breast

European Community Multicentre Study on Antioxidants, Myocardial Infarction, and Cancer of the Breast
- (EUROMEC) tissue antioxidants and postmenopausal breast cancer, 441

Exposure
- arsenic
- drinking water, toenail samples, 849
- mitomycin C hypersensitivity and, 103
cadmium
- metallothionein gene expression and, 297
- chemical
- squamous and basal cell carcinoma risk, skin, 419

Environmental
Fatty acids
essential
and prostate cancer, editorial, 859
and prostate carcinoma risk, 889
omega-3
consumption biomarkers, prostatic carcinoma, 115
omega-6
and prostate carcinoma risk, 889
Feces
mucosal diacylglycerol levels, proliferation and, 937
Fertilizers
parental use, testicular cancer, 3
Finnish reinforced plastics workers
styrene-exposed
glycophorin A mutations, 205
Flavonoids
quercetin
urinary metabolites, quantitation, 711
Floriculturists
peripheral WBC DNA adducts, 32P-postlabeling detection, 361
Fluid consumption
total
and lower urinary tract cancer risk, 161
Flukes, liver
infection
CYP2A6 and, 795
Folates
and colorectal cancer, male smokers, 487
Food frequency questionnaire
new carotenoid data base and, 907
Food groups
and colon cancer risk, 495
Food intake
and lower urinary tract cancer risk, 161
Freezers
upright mechanical temperature variations, 139
Fructose
urinary excretion, dietary intervention studies, 167
Fruit consumption
and cancer mortality, Caerphilly Study, 673
G
Galbladder adenocarcinoma
p53 mutations, 461
Gastric cancer
*H. pylori* and, meeting report, 477
Gastric cardia adenocarcinoma
risk factors, 761
Gastric juice fluids
nitrite levels, precancerous gastric lesions, 47
Gastric lesions
precancerous
*H. pylori* antibodies and, high-risk Chinese, 627
nitration, risk, 47
prevalence, Venezuela, 41
risk factors
nitration, 47
Genes
cyclin D1
expression, Barrett’s esophagus, 457
CYP1A1
Mspl polymorphism, and lung cancer susceptibility, 687
GSTM1
polymorphisms, lung cancer, 337
metallothionein (MT)
expression, cadmium exposure, 297
p53
codon 72 polymorphisms, lung cancer, 337
mutations, and occupational exposures, lung cancer, 997
mutations, esophageal carcinoma, 277
mutations, gallbladder adenocarcinomas, 461
mutations, intestinal-type Barrett’s esophagus, 559
mutations, radiation-associated lung cancer, 93
Genistein
soya diet and urine, quantification method, 407
Genotypies
aldehyde dehydrogenase-2
esophageal cancer and, Japanese males, 99
GSTM1
and anal cancer risk, 985
GSTM1-null
and bladder cancer, benzidine-exposed workers, 797
Genotyping
*NA*72
interchangeability with caffeine phenotyping, 449
Glucose-6-phosphate dehydrogenase
-deficient phenotypes
lead smelter workers, mortality, 223
Glutathione
plasma
dietary α-tocopherol supplementation and, 263
Glutathione S-transferase M1
and anal cancer risk, population-based case-control study, 985
and bladder cancer, benzidine-exposed workers, 797
polymorphisms, lung cancer, 337
Glycophorin A
mutations, styrene-exposed workers, 801
Greenhouse floriculturists
peripheral WBC DNA adducts, 32P-postlabeling detection, 361
Growth factor
epidermal receptor inhibitors, potential chemopreventives, 657
GST: see Glutathione S-transferase
H
HBV: see Hepatitis B virus
HCV: see Hepatitis C virus
Head and neck cancer
multiple cancer incidence among relatives and, 595
Helicobacter pylori
antibodies and precancerous gastric lesions, high-risk Chinese, 627
gastric cancer, meeting report, 477
Hematuria
before bladder cancer, 993
Hemoglobin adducts: see also 4-Aminobiphenyl-hemoglobin adducts
occupational styrene and styrene oxide exposure, 205
Hepatitis B
interactions with hepatitis C, hepatocellular carcinogenesis, 173
Hepatitis B surface antigen
 aflatoxin-albumin adducts and, Qidong County, 253
Hepatitis B virus
leukemias, case-control study, 227
Hepatitis C
interactions with hepatitis B, hepatocellular carcinogenesis, 173
Hepatitis C virus
leukemias, case-control study, 227
Hepatocellular carcinoma
acute intermittent porphyria and, morphology and mutations, 393
 aflatoxin B1 DNA adducts multiple risk factors, 613
hepatitis C and B infections, Taiwan, 173
Herpes simplex virus
type 2
HPV-related cervical tumors and, 541
Hispanics
breast cancer survival, New Mexico, 861
ovarian cancer incidence and mortality, New Mexico, 323
History, medical
squamous and basal cell carcinoma risk, skin, 419
History, reproductive
and thyroid cancer, women, 425
HLA: see Human leukocyte antigen
13-HO-DE: see 13-Hydroxyoctadecadienoic acid
Hodgkin’s disease
radiotherapy and, p53 mutations, associated lung cancer, 93
Hormone replacement therapy
and adenoanous polyps, 779
Hormones
serum
and breast cancer risk, 533
one-year reliability, women, 917
reproducibility, 835
sex
serum levels, reliability and validity, 923
steroid
soya diet and, premenopausal women, 63
HPV: see Human papillomavirus
HSV: see Herpes simplex virus
HTLV: see Human T-cell lymphotropic virus
Human leukocyte antigen
distribution, adult T-cell leukemia/lymphoma, 873
type
and nasopharyngeal carcinoma, 879
Human papillomavirus
DNA, invasive cervical carcinoma, 271
PCR-based DNA assay, interlaboratory agreement, letter, 483
-related cervical tumors
and smoking, oral contraceptive use, and, HSV-2, 541
and upper aerodigestive tract cancers, review, 567
Human papillomavirus-16/-18 E6 protein cervicovaginal, invasive cervical cancer, 329
Human T-cell lymphotropic virus
type I
-associated adult T-cell leukemia/lymphoma, HLA distribution, black patients, 873
-associated myelopathy/tropical spastic paraparesis, serum biomarker patterns, 699
leukemias, case-control study, 227
type II
leukemias, case-control study, 227
Hydrocarbons
chlorinated
blood levels, breast cancer, 467
1,3-Hydroxycyclohexadiene acic dehydrogenase
levels, neoplastic colon tissue, 53
Hyperplasia
atypical
papillary apocrine change and, 29
Hypersensitivity
mitomycin C, arsenic exposure biomarker, 103
Hysterectomy
and ovarian cancer, 933
I
Immune activation
blood biomarkers, pattern, 699
Immune-related conditions
adult acute leukemia, 867
Immunoassay
enzyme-linked kit
urinary estrogen metabolites
measurement, 727
Indians
cancer incidence rates, 749
Infections
hepatitis C and B, hepatocellular carcinogenesis, 173
herpes simplex virus type 2
HPV-related cervical tumors and, 541
liver fluke
CYP2A6 and, 795
Inference
causal, practice, 303
Inflammatory disease
pelvic and ovarian cancer risk, 667
Inner-city children
environmental tobacco smoke exposure, 135
Insulin
colon tumor promotion, rats, 1013
Intestinal crypts
aberrant, colon cancer biomarker, 355
PCNA, computer-assisted image analysis, 109
whole crypt mitotic count
rectal biopsy, reliability, 437
Intestinal-type Barrett’s metaplasia p53 mutations, 559
Intestine, large
adenomatous polyps
hormone replacement therapy and, 779
crypts
PCNA, computer-assisted image analysis, 109
Intestine, small
adenocarcinoma and carcinoid tumor incidence, adults, 81
Invasive cervical cancer
HPV DNA and, 271
HPV-16/-18 E6, p53, and bcl-2 protein, 329
Investigators
training programs, 141
Iron
intake
and colorectal cancer risk, 503
Isoflavones
soya diet and urine, quantification method, letter, 407
Italy, Northern
colorectal cancer
diet diversity and, 433
pancreatic cancer, attributable risks, 23
Italy, Western Liguria
greenhouse floriculturists
peripheral WBC DNA adducts, 13P- postlabeling detection, 361
J
Japanese males
esophageal cancer and aldehyde dehydrogenase-2 genotypes, 99
K
Karyotypes
environmental exposures and, acute myelocytic leukemia, 639
Keratin, actin
surrogate end point biomarkers
PCNA, 343
Kinase
tyrosine
epidermal growth factor receptor inhibitors, chemopreventives, 657
L
Labeling index quantification
bromodeoxyuridine
colonic proliferation measurement, reproducibility, 349
Large intestine
adenomatous polyps
hormone replacement therapy and, 779
crypts
PCNA, computer-assisted image analysis, 109
Larynx cancer
risk
CYP2D6 activity and tobacco and, 683
Lead smelter workers
G6PD-deficient phenotype
mortality, 223
Legumes
consumption
urine isoflavones, quantification method, letter, 407
Lesions, chromosomal
and lung cancer, 527
Lesions, precancerous
gastric
H. pylori antibodies and, high-risk Chinese, 627
nitrosation risk, 47
prevalence, Venezuela, 41
Leukemia
HBV, HCV, HTLV-I, HTLV-II and, 227
Leukemia, acute
adult
immune-related conditions, 867
Leukemia, acute lymphoblastic
immune-related conditions, 867
Leukemia, acute myelocytic
environmental exposures and karyotype, 639
Leukemia, acute myeloid
immune-related conditions, 867
Leukemia/lymphoma, adult T-cell
HLA distribution, 873
serum biomarker patterns, 699
Leukoplakia, oral
urinary biomarkers and, 521
Lifestyle
and prostate cancer risk, Sweden, 509
Liguria, Western
greenhouse floriculturists
peripheral WBC DNA adducts, 13P- postlabeling detection, 361
Lipids
peroxidation
-induced malondialdehyde-DNA adducts, breast tissue, 705
serum
and colorectal adenomas, 607
whole blood
stability at 4°C, 811
Liver fluke infection
CYP2A6 and, 795
Lower urinary tract cancer
risk factors, 161
Low-income minority women
self-reported breast and cervical cancer screening tests, validation, 721
Lung cancer
CARET prevention study
serum carotene, retinol, and tocopherol, 815
chromosomal lesions and, 527
GSTM1 and codon 72 p53 polymorphisms, 337
nonmalignant bronchial epithelium
trisomy 7, 631
p53 mutations and occupational exposures, 997
radiation-associated
p53 mutations, 93
risk
dietary nitrosomethylamine and. Uruguay, 679
mure drinking and, Uruguay, 515
susceptibility
CYPIA1 MspI polymorphism and, 687
Lung tumors
chemoprevention by phenethyl isothiocyanate, rat, 645
Lycopenes
cis-trans isomers, prostate concentrations, 823
Lymphoblastoid cells
mutagen sensitivity
DNA repair capacity and, 199
Lymphocytes
micronuclei
frequency, osteosarcoma, dogs, 653
G0, and tumor response, 653
Lymphoma adult T-cell
HLA distribution, 873
serum biomarker patterns, 699
Lymphoma non-Hodgkin's
mixed pesticide exposure, 11

M

Mailed intervention
high-risk women, 71
Malondialdehyde-DNA adducts
breast tissue, 705
Mammography
annual
mailed intervention and, high-risk women, 71
screening
cross-sectional vs prospective predictors, 845
stages of change
breast cancer risk perceptions and, 1005
Mute drinking
and lung cancer risk, Uruguay, 515
Maternal diet/vitamin use
and pediatric brain tumors, 599
Meats
cured
maternal consumption, and pediatric brain tumors, 599
Mechanical freezers
upright
temperature variations, 139
Medical conditions
and adenocarcinomas of esophagus and gastric cardia, 761
Medical history
squamous and basal cell carcinoma risk, skin, 419
Mediterranean Northwestern
GSTM1 and codon 72 p53 polymorphisms, lung cancer, 337
Melanoma
blood tyrosinase mRNA, 293
Men
Japanese
esophageal cancer and aldehyde dehydrogenase-2 genotypes, 99
lung cancer
mure drinking and, 515
smokers
folate status and colorectal cancer, 487
Mesothelioma pleural
simian virus 40 and, 473
Messenger RNA
tyrosinase
blood, melanoma, 293
Metallothionein
gene expression, cadmium exposure, 297
Metaplasia Barrett's
intestinal-type
p53 mutations, 559
4-(Methylthiuronium)-1-(3-pyridyl)-1-butanoate
lung tumors
chemoprevention by phenethyl isothiocyanate, rat, 645
urine metabolites, smokeless tobacco users, 521
Micronuclei
lymphocyte
frequency, osteosarcoma, dogs, 653
G0, and tumor response, 653
Micronutrients
colonic uptake and distribution, 913
Minnesota Cancer Prevention Research Unit
hormone replacement therapy and adenomatous polyps, case-control study, 779
Minority women
low-income
self-reported breast and cervical cancer screening tests, validation, 721
Mitomycin C
hypersensitivity, arsenic exposure biomarker, 103
Mitotic cells
whole crypt count, rectal biopsies, 437
MN antigen
cervical PAP smears, cervical dysplasia, 549
Mortality
adrenal cancer
smoking and, U.S. veterans, 79
cancer
fruit and vegetable consumption and, Caerphilly Study, 673
G6PD-deficient phenotype lead smelter workers, 223
ovarian cancer, New Mexico, 323
Mucosa
colonic diacylglycerol levels, proliferation and, 937
Multiple upper aerodigestive tract cancers
cancer incidence among relatives and, 595
Mutagenicity
urinary, benzenes-exposed workers, 979
Mutagen sensitivity
N-acetylcysteine supplementation and, 941
assay, statistical analysis, 191
dose-response relationship, case-control studies, 577
lymphoblastoid cell
DNA repair capacity and, 199
Mutations
acute intermittent porphyria, and hematopoietic carcinoma, 393
glycophorin A, styrene-exposed workers, 801
p53
bladder cancer, 33
esophageal carcinoma, China, 277
gallbladder adenocarcinoma, 461
intestinal-type Barrett’s esophagus, 559
and occupational exposures, lung cancer, 997
radiation-associated lung cancer, 93
somatostatin
glycophorin A, styrene-exposed workers, 205
Myelopathy
HTLV-I associated, serum biomarker pattern, 699

N

Nasopharyngeal cancer
HLA type and, 879
low-risk population, 587
Neoplasia see also Tumors
Neoplasia cervical intraepithelial
β-carotene treatment, phase II study, 929
New Mexico
breast cancer survival, 861
ovarian cancer incidence and mortality, 323
prostate cancer survival, ethnic variation, 247
Nipple aspiration
PSA levels, and breast cancer risk, 967
Nitrites
dietary
and lower urinary tract cancer risk, 161
gastric juice fluids, precancer gastric lesions, 47
Nitrosamine
and lower urinary tract cancer risk, 161
tobacco-specific
urine NNK metabolites, smokeless tobacco users, 521
Nitrosation
gastric lesion risk, 47
N-Nitroso compounds
urinary levels, precancerous gastric lesions, 47
Nitrosodimethylamine
dietary
and lung cancer risk, Uruguay, 679
NNK see 4-(Methylthiuronium)-1-(3-pyridyl)-1-butane
Nonlinear calibration curves
biomarker measurement variability, 57
Nonsteroidal anti-inflammatory drugs
and colorectal cancer, women, 955
Northern China
esophageal biopsy sampling procedure, reproducibility, 405
Northern Italy
colorectal cancer, diet diversity and, 433
pancreatic cancer, attributable risks, 23
Northern Sweden
hepatocellular carcinoma, acute intermittent porphyria and, 393
Northwestern Mediterranean
GSTM1 and codon 72 p53 polymorphisms, lung cancer, 337
Nuclear antigen
proliferating cell
computer-assisted image analysis, large intestine, 109
surrogate end point biomarker, actinic keratosis, 343
O

Obesity
renal cell cancer risk, 17

Occupational exposure
asbestos, bladder cancer, 33
benzidine
GSTM1 and bladder cancer, 979
p53 mutations and, lung cancer, 997
styrene
albumin and hemoglobin adducts, 205
glycophorin A mutations, 801
styrene oxide
albumin and hemoglobin adducts, 205

Omega-3 fatty acids
consumption biomarkers, prostatic carcinoma, 115

Omega-6 fatty acids
and prostate carcinoma risk, 889

Ophiothrix viverini infection
CYP2A6 and, 795

Oral contraceptives
HPV-related cervical tumors and, 541

Oral epithelial dysplasia
smoking and drinking and, 769

Oral leukoplakia
urinary biomarkers and, 521

Organochlorine
postprandial serum vs blood levels, 753

Osteosarcoma
lymphocyte micronuclei, frequency, 653

Ovarian cancer
incidence and mortality, New Mexico, 323 risk
pelvic inflammatory disease and, 667
tubal ligation or hysterectomy and, 933

Ovarian steroids
soya diet and, premenopausal women, 63

P

p53 protein
cervicovaginal, invasive cervical cancer, 329
codon 72 polymorphisms, lung cancer, 337
gene mutations
bladder cancer, 33
esophageal carcinoma, China, 277
gallbladder adenocarcinomas, 461
intestinal-type Barrett’s esophagus, 559
and occupational exposures, lung cancer, 997
radiation-associated lung cancer, 93
overexpression
risk factors, colorectal cancer, 285

Pancreatic cancer
attributable risks, Northern Italy, 23

Papanicolaou smears
cervical
MN antigen, cervical dysplasia, 549

Papillary apocrine change
breast cancer risk, 29

Paraparesis
tropical spastic, serum biomarker patterns, 699

Parasites
carcinogenic
infection, CYP2A6 and, 795

Parents
fertilizer use, testicular cancer, 3

PCNA: see Proliferating cell nuclear antigen

Pediatric brain tumors
maternal diet/vitamin use and, 599
prenatal tobacco smoke exposure and, study results, 127
tobacco smoke exposure and, 85

Pelvic inflammatory disease
and ovarian cancer risk, 667

People’s Republic of China: see China

Peripheral blood
tyrosinase mRNA, melanoma, 293
white blood cells
DNA adducts, floriculturists, 361

Pesticides
mixed exposure, non-Hodgkin’s lymphoma, 11
peripheral WBC DNA adducts, floriculturists, 361

Phenethyl isoioyoanate
chemoprevention of lung tumors, rat, 645

Phenotypes
G6PD-deficient
lead smelter workers, mortality, 223

Phenotyping
caffeine
CYP1A2, 231, 757
interchangeability with NAT2 genotyping, 449

Physical activity
and breast cancer risk, 155

Physician breast examinations
mailed intervention and, high-risk women, 71

Plasma glutathione
dietary α-tocopherol supplementation and, 263

Plastics, reinforced
styrene-exposed workers
glycophorin A mutations, 205

Pleural mesothelioma
simian virus 40 and, 473

Polychlorinated biphenyls
blood levels, breast cancer, 467

Polymerase chain reaction
HPV DNA assay, interlaboratory agreement, letter, 483
quantitative reverse transcription-metallothionein gene expression, cadmium exposure, 297

Polymorphisms
CYP1A1 Mspl, and lung cancer susceptibility, 687
GSTM1 and codon p53, lung cancer, 337

Polyp Prevention Trial I
rationale, design, baseline characteristics, 375

Polyp Prevention Trial II
dietary intervention, 385

Polyps, adenomatous
hormone replacement therapy and, 779
recurrent
and body mass index, 313

Polyps, colorectal
dietary antioxidant vitamins and, 147

Porphyria, acute intermittent
morphology and mutations, hepatocellular carcinoma, 393

Postmenopausal breast cancer
tissue antioxidants and, EURAMIC study, 441

Postmenopausal women
breast secretion
soy protein and, 785

serum hormone reliability, one-year, 917

Precancerous lesions, gastric
H. pylori antibodies and, high-risk Chinese, 627
nitrosation risk, 47
prevalence, Venezuela, 41

Premenopausal women
breast secretion
soy protein and, 785

serum hormone reliability, one-year, 917
soya diet and ovarian hormones, 63

Prenatal tobacco smoke exposure
and childhood brain tumors, study results, 127

Progeria
adult rare cancers in, 239

Progesterone
serum levels
reliability and validity, 923
reproducibility, 835

Proliferating cell nuclear antigen
computer-assisted image analysis, large intestine, 109
surrogate end point biomarker, actinic keratosis, 343

Prostate
lyocpene isomers, carotenoids, and retinol concentrations, 823

Prostate cancer
circulating vitamin D metabolites and, 121
essential fatty acids and, editorial, 859
omega-3 fatty acid consumption biomarkers, 115
risk
lifestyle factors and, Sweden, 509
omega-6 fatty acids and, 889
serum androgens and, 621
survival
ethnic variation, New Mexico, 247

Prostate-specific antigen
nipple aspirate fluid levels, and breast cancer risk, 967

Protein
bcl-2
cervicovaginal, invasive cervical cancer, 329
HPV-16/-18 E6
cervicovaginal, invasive cervical cancer, 329
p53
cervicovaginal, invasive cervical cancer, 329
overexpression, colorectal cancer, 285
soy and breast secretion, women, 785

PSA: see Prostate-specific antigen

Q

Qidong County, People’s Republic of China
Daxin aflatoxin-albumin adducts, temporal patterns, 253

Quantitative reverse transcription-polymerase chain reaction
metallothionein gene expression, cadmium exposure, 297
Quercetin flavonoids
urinary metabolites, quantitation, 711

Radiation
- associated lung cancer
p53 mutations, 93

Receptors
epidermal growth factor
inhibitors, potential chemopreventives,
657

Rectal adenomas
serum lipids and, 607

Rectum
biopsy whole crypt mitotic count,
reliability, 437
mucosal diacylglycerol levels, proliferation
and, 937

Reinforced plastics workers
styrene-exposed
glycophorin A mutations, 205

Renal cell cancer
risk factors
obesity, 17

Reproductive history
and thyroid cancer, women, 425

Research studies
Caerphilly fruit and vegetable consumption
study, 673
Carotene and Retinol Efficacy Trial, 815
β-carotene CIN treatment, 929
causal inference, practice, 303
dietary intervention
sucrose intake predictors, 167
European Community Multicentre Study
on Antioxidants, Myocardial
Infarction, and Cancer of the Breast,
441
GSTM1 genotypes and anal cancer risk,
985
HBV, HCV, HTLV-I, HTLV-II and
leukemias, 227
Minnesota Cancer Prevention Research
Unit
hormone replacement therapy and
adenomatous polyps, 779
mutagen sensitivity
dose-response relationship, 577
Polyp Prevention Trial I, 375
Polyp Prevention Trial II, 385
surrogate end points, 947
United States West Coast Childhood Brain
Tumor Study, 127

Retinol
colonic uptake and distribution, 913
prostate concentrations, 823
serum, CARET trial, 815

Retinyl palmitate
serum, CARET trial, 815

Reverse transcription-polymerase chain
reaction
quantitative
cell mutation, gene expression,
cadmium exposure, 297

Sampling
esophageal biopsy procedure, reproducibility, 405

Screening
cervical cancer, new developments, 853

mammography
- cross-sectional vs. prospective predictors,
845
physician breast examinations
mailed intervention and, 71
self-reported tests
breast and cervical cancer, validation,
721

Self-reported screening tests
breast and cervical cancer, validation, 721

Sensitivity: see also Hypersensitivity
mutagen
N-acetylcycteine supplementation and,
941
assay, statistical analysis, 191
dose-response relationship, case-control
studies, 577
lymphotblastoid cell, DNA repair
capacity and, 199

Serum
androgen levels
and breast cancer risk, 533
and prostate cancer, 621
biomarkers
immune activation, pattern, 699
β-carotene, CARET trial, 815
estrogen levels
and breast cancer risk, 533
hormones
levels, reproducibility, 835
one-year reliability, women, 917
lipids
and colorectal adenomas, 607
organochlorine levels, postprandial, 753
retinol, CARET trial, 815
retinyl palmitate, CARET trial, 815
sex hormone levels
reliability and validity, 923
α-tocopherol, CARET trial, 815

Sex hormones
serum levels, reliability and validity, 923

Simian virus 40
and pleural mesothelioma, 473

Sister chromatid exchange
mitomycin C-induced
hypersensitivity, arsenic exposure
biomarker, 103

Skin cancer
risk factors
chemical exposures and medical history,
419

Small intestine
adenocarcinoma and carcinoid tumor
incidence, adults, 81

Smoke, tobacco
- exposure
colonic brain tumors and, 85
environmental, inner-city children, 135
prenatal, and childhood brain tumors, 127

Smoking
adrenal cancer mortality, United States
veterans, 79
and breast cancer, 399
folic status and colorectal cancer, men,
487
HPV-related cervical tumors and, 541
oral epithelial dysplasia, 769
p53 mutations and, bladder cancer, 33
and thyroid cancer, women, 425

Socioeconomic factors
and adenocarcinomas of esophagus and
gastric cardia, 761

Somatic cell mutations
glycophorin A, styrene-exposed workers,
205

Soya diet
isoflavones, quantification method, 407
and steroid hormones, premenopausal
women, 63

Soy protein
and breast secretion, women, 785

Spastic paraparesis
tropical
serum biomarker patterns, 699

Squamous cell carcinoma, skin
risk factors
chemical exposure and medical history,
419

Steroid hormones
soya diet and, premenopausal women, 63

Stockholm, Sweden
colorectal cancer risk
dietary calcium, vitamin D and, 897

Stomach cancer
H. pylori and, meeting report, 477

Stomach lesions
precancerous
H. pylori antibodies and, high-risk
Chinese, 627
nitrosation risk, 47
prevalence, Venezuela, 41
risk factors
nitrosation, 47

Styrene
occupational exposure
albumin and hemoglobin adducts, 205
glycophorin A mutations, 801

Styrene oxide
occupational exposure
albumin and hemoglobin adducts, 205

Sucrose
urinary excretion, dietary intervention
studies, 167

Surrogate end points
biomarkers
PCNA, actinic keratosis, 343
cancer research, review, 947

Sweden
Northern
hepatocellular carcinoma, acute
intermittent porphyria and, 393
Stockholm
colorectal cancer risk
dietary calcium, vitamin D and, 897

Taiwan
hepatocellular carcinoma
hepatitis C and B infections, 173

T cells
HTLV type I
- associated adult T-cell
leukemia/lymphoma, HLA
distribution, 873
- associated myelopathy/tropical spastic
paraparesis, serum biomarker patterns,
699
leukemias, 227

HTLV type II, leukemias, 227
leukemia/lymphoma, adult
HLA distribution, 873
serum biomarker patterns, 699

Temperature
upright mechanical freezers, variations, 139

Testicular cancer
parental use of fertilizers and, 3

Testosterone
serum levels
reliability and validity, 923
whole blood
stability at 4°C, 811

Thyroid cancer
risk factors
reproductive history and cigarette smoking, women, 419

Tissue, breast
malondialdehyde-DNA adducts, 705

Tissue, colon
neoplastic
13-HODE dehydrogenase, 53

Tissue antioxidants
and postmenopausal breast cancer, EURAMIC study, 441

Tissue suppressor genes
p53
mutations, gallbladder adenocarcinomas, 461

Tobacco
and adenocarcinomas of esophagus and gastric cardia, 761
and larynx cancer risk, 683
smokeless
urine NNK metabolites, 521

Tobacco smoke
exposure
childhood brain tumors and, 85
environmental, inner-city children, 135
prenatal, and childhood brain tumors, 127

Tobacco smoking: see Smoking
α-Tocopherol
dietary supplementation
and glutathione and DNA repair, 263
serum, CARET trial, 815

Tocopherols
colonic uptake and distribution, 913

Tofu
and breast cancer risk, Asian-Americans, 901

Total fluid consumption
and lower urinary tract cancer risk, 161

Toxicity
difluoromethylornithine, evaluation, 371

Training programs
cancer prevention and control investigators, 141

Trisomy
nonmalignant bronchial epithelium, lung cancer, 631

Tropical spastic paraparesis
serum biomarker patterns, 699

Tubal ligation
and ovarian cancer, 933

Tumor-associated antigen
DD23, bladder cancer marker, 971
MN
cervical Pap smears, cervical dysplasia, 549

Tumors
cisplatin response
EGF lymphocyte micronuclei and, osteosarcoma, 653

Tumors, brain
childhood
maternal diet/vitamin use and, 599
prenatal tobacco smoke exposure and, study results, 127
tobacco smoke exposure and, 85

Tumors, cervical
HPV-related
and smoking, oral contraceptive use, and HSV-2, 541

Tumors, colon
13-HODE dehydrogenase levels, 53
insulin promotion, rats, 1013

Tumors, lung
chemoprevention by phenethyl isothiocyanate, rat, 645

Tumor suppressor genes
p53
codon 72 polymorphisms, lung cancer, 337
mutations, bladder cancer, 33
mutations, esophageal carcinoma, 277
mutations, intestinal-type Barrett’s esophagus, 559
mutations, radiation-associated lung cancer, 93

Tyrosinase
mRNA
blood, melanoma, 293

Tyrosine kinase
epidermal growth factor receptor inhibitors, chemopreventives, 657

United States: see also specific states
African American males
biomarkers of omega-3 fatty acid consumption, prostatic carcinoma, 115
breast carcinoma in situ incidence and treatment, regional differences, 317
Caucasians
biomarkers of omega-3 fatty acid consumption, prostatic carcinoma, 115
HLA type and nasopharyngeal carcinoma, 879
veterans
adrenal cancer mortality, smoking and, 79

United States West Coast Childhood Brain Tumor Study
prenatal tobacco smoke exposure and childhood brain tumors, 127

Upper aerodigestive tract cancer
human papillomavirus and, review, 567
multiple cancer incidence among relatives and, 595

Urinary tract
lower, cancer
risk factors, 161

Urinary tract
lower, cancer
risk factors, 161

Urine
biomarkers
and oral leukoplakia, 521
and diet, 167
estrogen metabolites

enzyme-linked immunosassay kit
measurement, 727
isoflavones, quantification method, letter, 407
mutagenicity, benzidine-exposed workers, 979
N-nitroso compound levels, precancerous gastric lesions, 47
NNK metabolites, smokeless tobacco users, 521
quercetin metabolites, quantitation, 711

Uruguay
lung cancer risk
dietary nitrosodimethylamine and, 679
mate drinking and, 515

V

Vegetables
brassica and cancer risk, review, 733
consumption and cancer mortality, Caerphilly Study, 673

Venezuela
precancerous stomach lesions, prevalence, 41

Veterans, U. S.
adrenal cancer mortality, smoking and, 79

Viruses
hepatitis B
hepatocellular carcinogenesis, 227
leukemias, 227
hepatitis C
hepatocellular carcinogenesis, 227
leukemias, 227
herpes simplex virus 2
HPV-related cervical tumors and, 541
human papillomavirus
DNA, invasive cervical carcinoma, 271
PCR-based DNA assay, interlaboratory agreement, 483
-related cervical tumors, 541
and upper aerodigestive tract cancers, review, 567
human papillomavirus-16-18 E6 protein cervicovaginal, invasive cervical cancer, 329
human T-cell lymphotropic, type I
-associated myelopathy/tropical spastic paraparesis, serum biomarker patterns, 699
leukemias, 227
human T-cell lymphotropic, type II
leukemias, 227
simian virus 40, and pleural mesothelioma, 473

Vitamin A
dietary intake
and colorectal adenomas, 147
whole blood, stability at 4°C, 811

Vitamin C
dietary intake
and colorectal adenomas, 147
whole blood, stability at 4°C, 811

Vitamin D
circulating metabolites, prostate cancer, 121
and colorectal cancer, Stockholm, 897
Vitamin E
- dietary intake and colorectal adenomas, 147
- whole blood, stability at 4°C, 811

Vitamins
- antioxidant dietary intake and colorectal adenomas, 147
- maternal consumption and pediatric brain tumors, 599

W

Water, drinking
toenail arsenic concentrations and, 849

Water intake
and colon cancer risk, 495

Werner syndrome
rare cancers in, 239

Western Liguria, Italy
greenhouse floriculturists

peripheral WBC DNA adducts, 32P-postlabeling detection, 361

White blood cells
peripheral DNA adducts, floriculturists, 361

Whites: see Caucasians

Whole blood
stability at 4°C, 811

Whole crypt mitotic count
rectal biopsy, reliability, 437

Women
breast secretion soy protein and, 785
colorectal cancer NSAID use and, 955
dietary intervention low-fat high-carbohydrate, long-term effects, 217
high-risk of breast cancer mailed intervention and, 71

low-income minority self-reported breast and cervical cancer screening tests, validation, 721
New Mexico breast cancer survival, 861
premenopausal soya diet and ovarian hormones, 63
serum hormone levels, reproducibility, 835
serum hormone reliability, one-year, 917
thyroid cancer reproductive history and cigarette smoking and, 419
younger endometrial cancer, familial risk, 411

Workers: see Occupational exposure

Y

Younger women
endometrial cancer, familial risk, 411